Skip to main content

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Active, not recruiting · Phase 1, Phase 2 · NCT05551936

Conditions: Follicular Lymphoma

At a glance

Research payments reported, 2025
$2.3M
U.S. investigators named
4
Sites paid
6
Planned or actual enrollment
42

About the trial

Sponsor
Vaishalee Kenkre (with Epizyme, Inc., University of Wisconsin, Madison)
Tested
Bendamustine (drug), Rituximab (drug), Tazemetostat (drug)
Dates
Started 2023-01-26; completion 2027-05
Results posted
Not yet

This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendamustine 90 mg/m2 IV on days 1 and 2 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up to three cycles. Following this, patients will receive tazemetostat twice daily on days 1-28 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up to three cycles.

From ClinicalTrials.gov, last updated 2026-02-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Ipsen Biopharmaceuticals, Inc reported $2.3M in research payments for this study in 2025 (16 payments).

Products named: Tazverik

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.